Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy

August 25, 2025 10:00 AM

Vexing challenges await cancer researchers every day -- not just in finding new molecules -- but now, increasingly, in finding new ways to make tumors more vulnerable to existing drugs.Tumors have their own defense mechanisms, designed to thwart therapeutic intruders, and the immune system is often unable to mount an effective response.Dozens of companies are working in this area but Actuate Therapeutics (NASDAQ:ACTU) reports it has made more...

Read more

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

August 25, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating agitation in patients with Alzheimer's disease. The Company has added a clinical site at the Lynn Health Science Institute (LHSI) in Oklahoma City, Oklahoma.Dr. Carl Griffin, MD, will serve as the Principal Investigator for the site. Dr. Griffin brings extensive experience in...

Read more

Invitation to FluoGuide A/S (Nasdaq:FLUO) Webcast on 28 August 2025

August 22, 2025 7:10 AM

FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q2 2025 on Thursday 28 August 2025.The following event will take place later that day:A live webcast for shareholders, analysts, investors and representatives of the media:Topic: FluoGuide Operational and Financial Results for Q2 2025Date: Thursday 28 August 2025Time: 14.00 CETThe webcast is hosted by analyst Christian Binder, Redeye. FluoGuide is represented by CEO Morten...

Read more

Interim Report April - June 2025

August 22, 2025 2:20 AM

Vicore Pharma Holding AB (STO: VICO) ("Vicore"), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the second quarter 2025."Vicore's Phase 2b ASPIRE trial remains on track and is expected to complete enrollment in the first half of next year.During the second quarter, Vicore continued to execute with focus, ensuring efficient site activation and enrollment for...

Read more

Notice Of Annual General Meeting in Biovica International AB

August 22, 2025 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are hereby invited to the annual general meeting to be held on Tuesday 23 September 2025, at 10.00 CEST at Conference Hubben, Dag Hammarskjölds Väg 38 in Uppsala.Right to attend the general meetingShareholders wishing to attend the annual general meeting must:i. on the record date, which is on Monday...

Read more

NAYA Therapeutics Partners With IONETIX to Build a US Production & Supply Network for Astatine-211 Targeted Alpha Therapies

August 21, 2025 11:35 AM

MIAMI, FL and LANSING, MI / ACCESS Newswire / August 21, 2025 / NAYA Therapeutics ("NAYA"), a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of astatine-211 (²¹¹At) targeted alpha therapies (TATs) and bifunctional antibodies today announced that it has entered into a partnership agreement with Ionetix, a cyclotron and technology company providing full-service...

Read more

Groundwork BioAg Co-Founder and CEO Yossi Kofman Appointed Chairman as Alon Werber Named CEO

August 20, 2025 9:30 AM

Groundwork BioAg, a global leader in mycorrhizal solutions for commercial agriculture and pioneer durable carbon dioxide removal (CDR), today announced that co-founder and CEO Dr. Yossi Kofman will become chairman of the board as seasoned executive Alon Werber is named Chief Executive Officer. Building on established market penetration in 23 countries - including the United States, Brazil, India, and China -Groundwork BioAg aims to deepen its...

Read more

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

August 20, 2025 8:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and unmet medical needs announced positive results from a recent pharmacokinetic (PK) simulation analysis of its lead clinical asset, TH104, a buccal film formulation of nalmefene. The results reinforce the potential of TH104 as a prophylactic countermeasure...

Read more

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

August 20, 2025 7:00 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received a not-approvable letter from the U.S. Food & Drug Administration (FDA) in response to its Premarket Approval (PMA) application for VenoValve®, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI). The letter...

Read more

Alligator Bioscience Provides Highlights from R&D Event 2025

August 20, 2025 6:35 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, provides key highlights from its R&D event held on 19 August 2025. The event featured presentations from Alligator's management and scientific leadership, outlining Alligator's clinical progress, upcoming milestones, and strategic outlook.Key takeaways from the event include:Mitazalimab - Phase 3...

Read more

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

August 19, 2025 9:00 AM

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, reported its financial results for the quarter ended June 30, 2025.Highlights in the quarter include:Accelerated progress on the Company's Phase 2 CALMA trial in Alzheimer's diseaseProgress in the development of MINT-ADExtension of its undrawn $12M credit facilityRam...

Read more

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

August 19, 2025 2:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, will report its unaudited half-year financial results for the six months ended 30 June 2025, on Wednesday, 27 August 2025.A virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Juho Jalkanen, Chief Executive Officer, Yrjö Wichmann, Chief...

Read more

Inside Information: Faron to Advance Bexmarilimab into a Registrational Phase 2/3 Study in Treatment-Naïve (frontline) HR-MDS after Positive Meeting with the FDA

August 18, 2025 2:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces it has received positive and valuable feedback from the U.S. Food and Drug Administration (FDA) regarding the proposed clinical development plan leading to approval for bexmarilimab , its wholly-owned, novel precision cancer immunotherapy.The feedback was received as part...

Read more

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

August 15, 2025 9:21 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows:Date and Time: Thursday, August 21, 2025 at 2:00 PM ETPresenter: Robert Berman, enVVeno Medical's...

Read more

Lobe Sciences Announces the Closing of the Previously Announced Private Placement

August 14, 2025 11:00 PM

Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases, announces the closing of the non-brokered private placement (the "Offering") of up to 8,535,625 common share of the Company (each, a "Share") at a price of $0.04 per Share for gross proceeds of up to $341,425 CAD. This offering was previously announced on July...

Read more

Yakir Abadi, Recognized Fintech and Blockchain Leader, Joins AppYea (OTCQB: APYP) as CEO

August 14, 2025 8:35 AM

AppYea Inc. (OTCQB:APYP) today announced the appointment of Yakir Abadi as Chief Executive Officer and director and Eldar Edmond Grady as Executive Chairman of the Board. This move brings two highly accomplished individuals into key roles - leaders with the experience, discipline, and market knowledge to create real value for shareholders.Yakir Abadi is regarded as one of Israel's leading voices and entrepreneurs in fintech, blockchain, and...

Read more

Alligator Bioscience to Host Virtual R&D Day on 19 August 2025

August 14, 2025 7:15 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announces that it will host a virtual R&D Day on Tuesday, 19 August 2025 at 4 p.m. CEST. The event will provide an in-depth update on Alligator's R&D pipeline, with a primary focus on its lead candidate mitazalimab, ahead of the upcoming TO 13 warrant exercise period (1-15 September 2025).During...

Read more

Biovica Carries Out a Directed Share Issue of Approximately MSEK 42.2

August 13, 2025 11:50 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The Board of Directors of Biovica International AB (publ) ("Biovica" or the "Company") announced on 5 August 2025 the outcome of the fully guaranteed new issue of class A and class B shares of approximately MSEK 80.1 with preferential rights for the Company's shareholders (the "Rights Issue"). In view of the outcome, the Board of Directors has today resolved to exercise the option of...

Read more

National Adoption of WATS3D Accelerates as Cooper University Health Care Physicians Advance Early Detection of Esophageal Disease

August 13, 2025 10:00 AM

The WATS3D test system, an AI-powered diagnostic platform for esophageal disease, continues to gain national traction as Cooper University Health Care Gastroenterologists Anthony Infantolino, MD, FACP, FACG, AGAF, MASGE and Christina Tofani, MD, FACG, FASGE continue to integrate the test into clinical practice. Cooper University Health Care's Division of Gastroenterology is dedicated to providing patients with the most advanced diagnostic and...

Read more

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

August 13, 2025 8:01 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today announced a significant expansion of its intellectual property portfolio for TH-104, its novel transmucosal film. The new patents, recently granted and allowed across key global markets, will enable the Company's...

Read more